Instagram Ern-EyeFacebook Ern-EyeTwitter Ern-EyeLinkedIn Ern-EyeYouTube Ern-EyeHow to use the speech recognition tool?
NCT03913143
ILLUMINATE
A double-masked, randomized, controlled, multiple-dose study to evaluate the efficacy, safety, tolerability and systemic exposure of QR-110 in Subjects with Leber’s Congenital Amaurosis (LCA) due to c.2991+1655A>G mutation (p.Cys998X) in the CEP290 gene (Illuminate).
Type: Interventional
Status of the trial: Active, Not recruiting
Orphan Drug Recognition: No
Inclusion
- Opening Date: 2019-04-04
- Closing Date: 2021-12-04
Criteria
Children: Yes
Adults: Yes
Funder Type: industry
HCP: Principal investigators
- Ghent University Hospital, Ghent, Belgium
- CARGO, Hôpitaux Universitaires de Strasbourg, France
- Centre for Ophthalmology, University Eye Hospital, Tübingen, Germany
- Universitätsklinikum Gießen und Marburg GmbH, Gießen, Germany
- Radboud university medical center, Nijmegen, Netherlands
- Moorfields Eye Hospital NHS Foundation Trust
HCP: Other investigators
Within ERN-EYE members
Principal investigators
Other investigators
Workgroups
Retinal Rare Eye Diseases (WG1)
This ERN is supported by:
